ReviewThe oncologist2025

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.

Daniel Lenihan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.